A Phase 4 interventional study of Saizen and Saizen in Growth Hormone Deficiency and Turner Syndrome, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 13 sites in 13 countries. Open to participants aged 2 Years to 16 Years. Per ClinicalTrials.gov, last updated 2018-06-26.
Sponsored by Merck KGaA, Darmstadt, Germany · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies testing Human Growth Hormone in Dwarfism, Pituitary — 3 open to participants now, 3 under way, 2 of them phase 3. Human Growth Hormone · Dwarfism, Pituitary.
Among the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, this one is the 8th largest by enrollment, is one of 5 that started in 2005, is one of 19 in phase 4, and was the 16th registered.
252 studies on the registry are indexed under Dwarfism, Pituitary; 30 are open to participants now.
Browse Dwarfism, Pituitary studies →3 of the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary are open now, in 1 country. Recruiting first, the newest first:
VA Office of Research and Development · Sites in United States
Ages 21–55
Baylor College of Medicine · Sites in United States
Ages 18–64
Changchun GeneScience Pharmaceutical Co., Ltd.
Ages 6 mo–17 yrs
By country, each count listing its studies:
Human Growth Hormone: first FDA approval 1986 (HUMATROPE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 20 Dwarfism, Pituitary studies recruiting now, 5 (25%) set no upper age limit and 12 (60%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.
This study: 2 Years to 16 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 8 · Phase 3 24 · Phase 4 19
First in 1997; this study’s year is marked. 5 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 318 is above the median of 60 across 169 interventional studies indexed under Dwarfism, Pituitary.
Median enrollment 66 across the 60 interventional studies. Of the 46 that completed or were terminated, 17 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
42 of 60 have an industry lead sponsor. The 10 most frequent:
Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.
13 studies in Dwarfism, Pituitary by Merck KGaA, Darmstadt, Germany: none open now, none under way, none of them phase 3. Of 13 finished, 7 (54%) have results posted.
Among the 13 studies in Dwarfism, Pituitary by Merck KGaA, Darmstadt, Germany, this one is the 2nd largest by enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2005, is one of 6 in phase 4, and was the 2nd registered.
Merck KGaA, Darmstadt, Germany’s Dwarfism, Pituitary studies by the year they started, since 2003.
2 of the studies testing Human Growth Hormone in Dwarfism, Pituitary that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04867317Phase 3VA Office of Research and DevelopmentGrowth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD) | 2027-02-28 |
| NCT05355272Baylor College of MedicineGrowth Hormone Replacement in Veterans With GWI and AGHD (GWIT) | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 60 studies testing Human Growth Hormone in Dwarfism, Pituitary, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck KGaA, Darmstadt, Germany’s 13 in Dwarfism, Pituitary:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study aims at identifying the predictive markers after one month of Saizen therapy in Growth Hormone Deficiency (GHD) and Turner Syndrome children.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A) GHD: documented pre-established diagnosis of GHD with a growth hormone (GH) peak response of \<10 microgram per liter (mcg/L) with 2 GH stimulation tests, without priming with oestradiol.
B) Turner syndrome: documented pre-established diagnosis by karyotype.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Saizen
Drug: Saizen
Subjects with TS will receive SAIZEN® as subcutaneous injection at a dose of 0.050 milligram per kilogram (mg/kg) of body weight per day (within the recommended dosage 0.045-0.050 mg/kg body weight) for a period of 1 month
Subjects with GHD will receive SAIZEN® as subcutaneous injection at a dose of 0.035 mg/kg of body weight per day (within the recommended dosage 0.025-0.035 mg/kg body weight) for a period of 1 month.
Change From Baseline in Insulin Like Growth Factor-1 Standard Deviation Score (IGF-1 SDS) at Month 1
IGF-1 SDS was calculated using the Elmlinger reference method. Change in within subject IGF-1 levels (standard deviation scores) at Month 1 from Baseline was assessed. Descriptive statistics were determined for the Baseline and Month 1 assessments, and also for the level of change between these two assessments. If either the Baseline or Month 1 IGF-1 level was missing, then the within-subject change in IGF-1 was assumed to be missing.
Time frame: Baseline, Month 1
Change From Baseline in Insulin-like Growth Factor Binding Protein - 3 (IGFBP-3) Level at Month 1
Time frame: Baseline, Month 1
Change From Baseline in Fasting Glucose Levels at Month 1
Time frame: Baseline, Month 1
Change From Baseline in Fasting Insulin Levels at Month 1
Time frame: Baseline, Month 1
Change From Baseline in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) at Month 1
HOMA-IR is used to assess insulin resistance and calculated by an empirical mathematical formula based on fasting plasma glucose and fasting plasma insulin levels. HOMA-IR = fasting plasma insulin (picomole/liter \[pmol/L\]) \* fasting plasma glucose (millimole/liter \[mmol/L\]) divided by 22.5.
Time frame: Baseline, Month 1
Change From Baseline in Bone Alkaline Phosphatase Levels at Month 1
Time frame: Baseline, Month 1
First informed consent date: May 2005. Clinical data cutoff date: Oct 2007, Study completion date: Sep 2007.
| Milestone | Turner Syndrome (TS) | Growth Hormone Deficiency (GHD) |
|---|---|---|
| Started | 149 | 169 |
| Completed | 147 | 167 |
| Not completed | 2 | 2 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Other | 1 | 2 |
IGF-1 SDS was calculated using the Elmlinger reference method. Change in within subject IGF-1 levels (standard deviation scores) at Month 1 from Baseline was assessed. Descriptive statistics were determined for the Baseline and Month 1 assessments, and also for the level of change between these two assessments. If either the Baseline or Month 1 IGF-1 level was missing, then the within-subject change in IGF-1 was assumed to be missing.
| Standard deviation score (SDS) | Turner Syndrome (TS) | Growth Hormone Deficiency (GHD) |
|---|---|---|
| Change From Baseline in Insulin Like Growth Factor-1 Standard Deviation Score (IGF-1 SDS) at Month 1 | 1.7692 ± 1.1889 | 1.4007 ± 0.9811 |
| milligram per liter (mg/L) | Turner Syndrome (TS) | Growth Hormone Deficiency (GHD) |
|---|---|---|
| Change From Baseline in Insulin-like Growth Factor Binding Protein - 3 (IGFBP-3) Level at Month 1 | 0.86 ± 0.96 | 0.69 ± 0.81 |
| millimoles per liter (mmol/L) | Turner Syndrome (TS) | Growth Hormone Deficiency (GHD) |
|---|---|---|
| Change From Baseline in Fasting Glucose Levels at Month 1 | 0.22 ± 0.8 | 0.13 ± 0.65 |
| picomole per liter (pmol/L) | Turner Syndrome (TS) | Growth Hormone Deficiency (GHD) |
|---|---|---|
| Change From Baseline in Fasting Insulin Levels at Month 1 | 47.7 ± 177.2 | 26.9 ± 79.8 |
HOMA-IR is used to assess insulin resistance and calculated by an empirical mathematical formula based on fasting plasma glucose and fasting plasma insulin levels. HOMA-IR = fasting plasma insulin (picomole/liter \[pmol/L\]) \* fasting plasma glucose (millimole/liter \[mmol/L\]) divided by 22.5.
| picomole per liter *millimole per liter | Turner Syndrome (TS) | Growth Hormone Deficiency (GHD) |
|---|---|---|
| Change From Baseline in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) at Month 1 | 2.132 ± 10.296 | 1.061 ± 3.885 |
| Units per liter (U/L) | Turner Syndrome (TS) | Growth Hormone Deficiency (GHD) |
|---|---|---|
| Change From Baseline in Bone Alkaline Phosphatase Levels at Month 1 | 21.13 ± 80.68 | 14.78 ± 25.23 |
Collected over Adverse events were captured from first dose until at least 4 weeks following the last SAIZEN® administration or the post-treatment visit, whichever represented the longer period (up to a maximum of 2 months).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Turner Syndrome (TS) | — | 0/149 (0%) | 36/149 (24.2%) |
| Growth Hormone Deficiency (GHD) | — | 1/169 (0.6%) | 51/169 (30.2%) |
| Event | Turner Syndrome (TS) | Growth Hormone Deficiency (GHD) |
|---|---|---|
| Tonsillitis streptococcalInfections and infestations | 0/149 | 1/169 |
| Event | Turner Syndrome (TS) | Growth Hormone Deficiency (GHD) |
|---|---|---|
| HeadacheNervous system disorders | 8/149 | 12/169 |
| PyrexiaGeneral disorders | 6/149 | 9/169 |
| CoughRespiratory, thoracic and mediastinal disorders | 5/149 | 2/169 |
| NasopharyngitisInfections and infestations | 4/149 | 2/169 |
| VomitingGastrointestinal disorders | 3/149 | 4/169 |
| Productive coughRespiratory, thoracic and mediastinal disorders | 3/149 | 0/169 |
| Upper respiratory tract infectionInfections and infestations | 3/149 | 2/169 |
| DiarrhoeaGastrointestinal disorders | 1/149 | 3/169 |
| DizzinessNervous system disorders | 2/149 | 1/169 |
| Ear infectionInfections and infestations | 2/149 | 0/169 |
| Age, Continuous(years) | Turner Syndrome (TS) | Growth Hormone Deficiency (GHD) | Total |
|---|---|---|---|
| Mean | 9.3 ± 4.08 | 8.94 ± 3.17 | 9.11 ± 3.62 |
| Sex: Female, Male(Participants) | Turner Syndrome (TS) | Growth Hormone Deficiency (GHD) | Total |
|---|---|---|---|
| Female | 149 | 63 | 212 |
| Male | 0 | 106 | 106 |
Ran from May 2005 to primary completion in Sep 2007, 27 months.
Results were first posted in Mar 2018, 10 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Human Growth Hormone
Merck KGaA, Darmstadt, Germany →